Clinical trials: Non-Squamous Non-Small Cell Lung Cancer
Advanced Solid Tumor, Non Small Cell Lung Cancer
Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors
The purpose of this study is to assess the safety and tolerability of BGB-A445 alone and in combination with tislelizumab in participants with advanced solid tumors; and to determine the maximum tolerated dose(s) (MTD) or maximum…
- Conditions
- Advanced Solid Tumor, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Nasopharyngeal Carcinoma (NPC)
- Trial name
- NCT04215978
- Testing
- BGB-A445, tislelizumab
- Where
- 30 sites in United States, Australia and 6 more
- Volunteers
- 204 people
- Sponsor
- BeiGene
Ovarian Cancer, Lung Cancer
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [177Lu]Lu-EVS459 and the safety and imaging properties of [68Ga]Ga-EVS459 in patients aged ≥ 18 years with advanced…
- Trial name
- NCT06376253
- Testing
- [68Ga]Ga-EVS459, [177Lu]Lu-EVS459
- Where
- Israel
- Volunteers
- 4 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumor
Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate BMS-986315 alone and in combination with nivolumab or cetuximab in participants with advanced solid tumors.
- Trial name
- NCT04349267
- Testing
- BMS-986315, nivolumab, cetuximab
- Where
- 8 sites in United States, Canada and 1 more
- Volunteers
- 44 people
- Sponsor
- Bristol-Myers Squibb
Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC)
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
The goal of this trial is to learn about the antibody GEN1042 when it is used alone and when it is used together with another antibody cancer drug, pembrolizumab (with or without chemotherapy), for treatment of participants with…
- Conditions
- Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Melanoma
- Trial name
- NCT04083599
- Testing
- GEN1042, Pembrolizumab, Cisplatin
- Where
- 76 sites in United States, Denmark and 10 more
- Volunteers
- 350 people
- Sponsor
- Genmab
Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer
Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/Melanoma
Conventional biopsy and surgical tumor resection are invasive procedures that capture only one instance of the progression of the tumor. However, the genome of tumor is not static, but it is constantly altered during treatment.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma
- Trial name
- NCT04490564
- Testing
- PD-L1 Kit
- Where
- 6 sites in Greece
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Pharmassist Ltd
Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
This is an exploratory, signal-finding, randomized, placebo-controlled, blinded, multi-center phase 2b trial of the anti-GDF-15 antibody Visugromab (CTL-002) at two different dose levels plus Nivolumab with Docetaxel versus…
- Trial name
- NCT07246863
- Testing
- Visugromab RDE (recommended dose for expansion), Visugromab 6mg/kg, Nivolumab
- Where
- 36 sites in United States, Germany and 5 more
- Volunteers
- 131 people
- Sponsor
- CatalYm GmbH
Non-small Cell Lung Cancer (NSCLC)
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
The purpose of this study is to determine the efficacy of CT-322 comparative to bevacizumab, both in combination with carboplatin and paclitaxel in the treatment of chemonaive subjects with recurrent or advanced non-squamous NSCLC
- Trial name
- NCT00850577
- Testing
- Paclitaxel, Carboplatin, CT-322
- Where
- 55 sites in United States, Brazil and 6 more
- Volunteers
- 255 people
- Sponsor
- Bristol-Myers Squibb
Liver Cancer (Locally Advanced or Metastatic), Lung Cancer (NSCLC)
A Study of SH009 Injection in Patients With Advanced Solid Tumors.
Evaluate the efficacy and safety of SH009 injection therapy for patients with advanced solid tumors
- Conditions
- Liver Cancer (Locally Advanced or Metastatic), Lung Cancer (NSCLC), Head and Neck Cancer Squamous Cell Carcinoma, Breast Cancer (Locally Advanced or Metastatic)
- Trial name
- NCT07390838
- Testing
- SH009
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
Carcinoma, Non-Small-Cell Lung
MYLUNG Consortium Study Protocol 2
This pragmatic study looks to quantify the testing timeline, operational barriers, and outcomes of biomarker-guided therapy in a large, community-based, and largely unselected patient population with early stage and advanced…
- Trial name
- MYLUNG (NCT05644808)
- Where
- 18 sites in United States
- Volunteers
- 1,002 people
- Sponsor
- US Oncology Research
Advanced MTAP-null Solid Tumors
A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)
The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of Anvumetostat alone and in combination with…
- Trial name
- MTAPESTRY 101 (NCT05094336)
- Testing
- Anvumetostat, Docetaxel, Comparator Anvumetostat Test Tablet
- Where
- 75 sites in United States, Australia and 12 more
- Volunteers
- 329 people
- Sponsor
- Amgen
Cervical Cancer, Head and Neck Squamous Cell Carcinoma
ITIL-168 in Advanced Solid Tumors
DELTA-2 is a phase 1 clinical trial to evaluate the safety, feasibility, and preliminary efficacy of ITIL-168 with pembrolizumab in participants with advanced cancer whose disease has progressed after standard therapy.
- Conditions
- Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer
- Trial name
- DELTA-2 (NCT05393635)
- Testing
- ITIL-168
- Sponsor
- Instil Bio
Advanced Squamous Tumors
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-711 as a monotherapy…
- Trial name
- NCT07241039
- Testing
- ABBV-711, Budigalimab
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 220 people
- Sponsor
- AbbVie
Adult Solid Tumor
CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2
The purpose of this study is to test the CANscript™ sensitivity assay, which is a new and different assay developed to test the sensitivity of different cancer types to physician selected therapies (both drugs and/or drug…
- Trial name
- ANCERS-2 (NCT03253575)
- Testing
- CANscript
- Where
- 30 sites in United States
- Volunteers
- 800 people
- Sponsor
- Mitra RxDx, Inc.
Solid Tumor, Non-Small Cell Lung Cancer
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in…
- Conditions
- Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma
- Trial name
- NCT04198766
- Testing
- INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg
- Where
- 42 sites in United States, Singapore and 2 more
- Volunteers
- 340 people
- Sponsor
- Inhibrx Biosciences, Inc
Solid Tumor, Adult, HCC - Hepatocellular Carcinoma
Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors
INDP-D101 is a Phase 1/2, open-label, multi-center, dose escalation and expansion study evaluating the safety, tolerability and clinical activity of Decoy20 as monotherapy and in combination with tislelizumab in patients with…
- Conditions
- Solid Tumor, Adult, HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer), Pancreatic Adenocarcinoma
- Trial name
- NCT05651022
- Testing
- Decoy20, Tislelizumab
- Where
- 12 sites in United States
- Volunteers
- 120 people
- Sponsor
- Indaptus Therapeutics, Inc
Non-Small Cell Lung Cancer
Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to evaluate YL202 monotherapy versus Docetaxel in participants with locally…
- Trial name
- NCT07416994
- Testing
- YL202, Docetaxel
- Where
- 2 sites in China
- Volunteers
- 440 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of BGB-B2033 alone or in combination with tislelizumab, with or without…
- Conditions
- Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors
- Trial name
- NCT06427941
- Testing
- BGB-B2033, Tislelizumab, Bevacizumab
- Where
- 51 sites in United States, Brazil and 7 more
- Volunteers
- 630 people
- Sponsor
- BeOne Medicines
Cervical Cancer, Gastric Cancer
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with select advanced malignancies.
- Conditions
- Cervical Cancer, Gastric Cancer, Stomach Cancer, Gastroesophageal Junction Cancer
- Trial name
- NCT03652077
- Testing
- INCAGN02390
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Incyte Corporation
Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
This is a phase 2 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) in front-line, PD-L1-high, locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC).
- Conditions
- Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer
- Trial name
- ARC-10 (NCT04736173)
- Testing
- Domvanalimab, Zimberelimab, Carboplatin
- Where
- 38 sites in United States, Hong Kong and 8 more
- Volunteers
- 169 people
- Sponsor
- Arcus Biosciences, Inc.
Carcinoma, Non-Small-Cell Lung
A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer
This is an international, multi-center, prospective, randomized, open-label Phase 3 clinical trial of the cancer stemness inhibitor napabucasin administered with weekly paclitaxel versus weekly paclitaxel alone in patients with…
- Trial name
- CanStem43L (NCT02826161)
- Testing
- Napabucasin, Paclitaxel
- Where
- 5 sites in United States
- Volunteers
- 4 people
- Sponsor
- Sumitomo Pharma America, Inc.